Anti-angiogenic compositions and methods of use

• US 20060127445A1
• Filed: 06/14/2005
• Published: 06/15/2006
• Est. Priority Date: 07/19/1993
• Status: Abandoned Application

• Current Assignee: Angiotech Pharmaceuticals Incorporated
• Original Assignee: Angiotech Pharmaceuticals Incorporated
• Inventors: Hunter, William L., Machan, Lindsay S., Arsenault, A. Larry, Jackson, John K., Burt, Helen M., Dordunoo, Stephen K.
• Application Number:
  US11/151,399
• Publication Number:
  US 20060127445A1
• Time in Patent Office: Days
• US Class Current: 424/426
• CPC Class Codes: A61K 2300/00 Mixtures or combinations of active ingredients, wherein at least one active ingredient is fully defined in groups A61K31/00 - A61K41/00
• CPC Class Codes: A61K 31/122 having the oxygen directly attached to a ring, e.g. quinones, vitamin K1, anthralin
• CPC Class Codes: A61K 31/136 having the amino group directly attached to the aromatic ring, e.g. benzeneamine
• CPC Class Codes: A61K 31/165 having aromatic rings, e.g. colchicine, atenolol, progabide
• CPC Class Codes: A61K 31/185 Acids; Anhydrides, halides or salts thereof, e.g. sulfur acids, imidic, hydrazonic or hydroximic acids hydroxamic acids A61K31/16; peroxy acids A61K31/327
• CPC Class Codes: A61K 31/203 Retinoic acids ; Salts thereof
• CPC Class Codes: A61K 31/335 having oxygen as the only ring hetero atom, e.g. fungichromin
• CPC Class Codes: A61K 31/337 having four-membered rings, e.g. taxol
• CPC Class Codes: A61K 31/426 1,3-Thiazoles
• CPC Class Codes: A61K 31/427 not condensed and containing further heterocyclic rings
• CPC Class Codes: A61K 31/4745 condensed with ring systems having nitrogen as a ring hetero atom, e.g. phenantrolines yohimbine derivatives, vinblastine A61K31/475; ergoline derivatives A61K31/48
• CPC Class Codes: A61K 31/519 ortho- or peri-condensed with heterocyclic rings
• CPC Class Codes: A61K 31/525 Isoalloxazines, e.g. riboflavins, vitamin B2
• CPC Class Codes: A61K 31/555 containing heavy metals, e.g. hemin, hematin, melarsoprol
• CPC Class Codes: A61K 31/565 not substituted in position 17 beta by a carbon atom, e.g. estrane, estradiol
• CPC Class Codes: A61K 31/57 substituted in position 17 beta by a chain of two carbon atoms, e.g. pregnane or progesterone
• CPC Class Codes: A61K 31/702 Oligosaccharides, i.e. having three to five saccharide radicals attached to each other by glycosidic linkages
• CPC Class Codes: A61K 33/00 Medicinal preparations containing inorganic active ingredients
• CPC Class Codes: A61K 33/06 Aluminium, calcium or magnesium; Compounds thereof , e.g. clay
• CPC Class Codes: A61K 33/24 Heavy metals; Compounds thereof
• CPC Class Codes: A61K 33/30 : Zinc; Compounds thereof
• CPC Class Codes: A61K 38/57 : from animals; from humans A61K38/553, A61K38/556 take precedence
• CPC Class Codes: A61K 45/06 : Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
• CPC Class Codes: A61K 9/0019 : Injectable compositions; Intramuscular, intravenous, arterial, subcutaneous administration; Compositions to be administered through the skin in an invasive manner non-active ingredients are additionally classified in A61K47/00
• CPC Class Codes: A61K 9/0048 : Eye, e.g. artificial tears
• CPC Class Codes: A61K 9/0051 : Ocular inserts, ocular implants
• CPC Class Codes: A61K 9/14 : Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles microspheres A61K9/16; microcapsules A61K9/50; nanocapsules, nanoparticles of the matrix type A61K9/51
• CPC Class Codes: A61K 9/1635 : obtained by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyvinyl pyrrolidone, poly(meth)acrylates
• CPC Class Codes: A61K 9/1641 : obtained otherwise than by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyethylene glycol, poloxamers
• CPC Class Codes: A61K 9/1647 : Polyesters, e.g. poly(lactide-co-glycolide)
• CPC Class Codes: A61K 9/1658 : Proteins, e.g. albumin, gelatin
• CPC Class Codes: A61K 9/5031 : obtained otherwise than by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyethylene glycol, poly(lactide-co-glycolide)
• CPC Class Codes: A61K 9/5146 : obtained otherwise than by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyethylene glycol, polyamines, polyanhydrides
• CPC Class Codes: A61K 9/5153 : Polyesters, e.g. poly(lactide-co-glycolide)
• CPC Class Codes: A61K 9/7007 : Drug-containing films, membranes or sheets A61K9/0041, A61K9/0043, A61K9/006, A61K9/0063 take precedence
• CPC Class Codes: A61L 2300/416 : Anti-neoplastic or anti-proliferative or anti-restenosis or anti-angiogenic agents, e.g. paclitaxel, sirolimus
• CPC Class Codes: A61L 2300/606 : Coatings
• CPC Class Codes: A61L 2300/622 : Microcapsules
• CPC Class Codes: A61L 2430/36 : for embolization or occlusion, e.g. vaso-occlusive compositions or devices artificial blood vessels A61L27/507
• CPC Class Codes: A61L 31/10 : Macromolecular materials
• CPC Class Codes: A61L 31/145 : Hydrogels or hydrocolloids
• CPC Class Codes: A61L 31/16 : Biologically active materials, e.g. therapeutic substances A61L31/047 takes precedence
• CPC Class Codes: A61P 1/04 : for ulcers, gastritis or reflux esophagitis, e.g. antacids, inhibitors of acid secretion, mucosal protectants
• CPC Class Codes: A61P 1/16 : for liver or gallbladder disorders, e.g. hepatoprotective agents, cholagogues, litholytics
• CPC Class Codes: A61P 11/00 : Drugs for disorders of the respiratory system
• CPC Class Codes: A61P 13/02 : of urine or of the urinary tract, e.g. urine acidifiers
• CPC Class Codes: A61P 19/02 : for joint disorders, e.g. arthritis, arthrosis
• CPC Class Codes: A61P 27/02 : Ophthalmic agents
• CPC Class Codes: A61P 35/00 : Antineoplastic agents
• CPC Class Codes: A61P 43/00 : Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
• CPC Class Codes: A61P 7/02 : Antithrombotic agents; Anticoagulants; Platelet aggregation inhibitors
• CPC Class Codes: A61P 7/04 : Antihaemorrhagics; Procoagulants; Haemostatic agents; Antifibrinolytic agents
• CPC Class Codes: A61P 9/00 : Drugs for disorders of the cardiovascular system
• CPC Class Codes: A61P 9/10 : for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
• CPC Class Codes: A61P 9/14 : Vasoprotectives; Antihaemorrhoidals; Drugs for varicose therapy; Capillary stabilisers
• CPC Class Codes: B82Y 5/00 : Nanobiotechnology or nanomedicine, e.g. protein engineering or drug delivery
• CPC Class Codes: C07C 233/64 : having carbon atoms of carboxamide groups bound to carbon atoms of six-membered aromatic rings
• CPC Class Codes: C07K 14/811 : Serine protease (E.C. 3.4.21) inhibitors
• CPC Class Codes: C08L 2203/02 : for biomedical use
• CPC Class Codes: C08L 23/08 : Copolymers of ethene C08L23/16 takes precedence
• CPC Class Codes: C08L 23/0853 : Vinylacetate
• CPC Class Codes: C08L 2312/00 : Crosslinking
• CPC Class Codes: C08L 2666/04 : Macromolecular compounds according to groups C08L7/00 - C08L49/00, or C08L55/00 - C08L57/00; Derivatives thereof
• CPC Class Codes: C08L 2666/06 : Homopolymers or copolymers of unsaturated hydrocarbons; Derivatives thereof
• CPC Class Codes: C08L 2666/18 : Polyesters or polycarbonates according to C08L67/00 - C08L69/00; Derivatives thereof
• CPC Class Codes: C08L 29/04 : Polyvinyl alcohol; Partially hydrolysed homopolymers or copolymers of esters of unsaturated alcohols with saturated carboxylic acids
• CPC Class Codes: C08L 67/04 : Polyesters derived from hydroxycarboxylic acids, e.g. lactones C08L67/06 takes precedence
• CPC Class Codes: Y10S 977/773 : Nanoparticle, i.e. structure having three dimensions of 100 nm or less
• CPC Class Codes: Y10S 977/915 : Therapeutic or pharmaceutical composition

Abstract

The present invention provides compositions comprising an anti-angiogenic factor, and a polymeric carrier. Representative examples of anti-angiogenic factors include Anti-Invasive Factor, Retinoic acids and derivatives thereof, and paclitaxel. Also provided are methods for embolizing blood vessels, and eliminating biliary, urethral, esophageal, and tracheal/bronchial obstructions.

Claims

1. A composition, comprising:

(a) a compound which disrupts microtubule function; and

(b) a polymeric carrier, with the proviso that said polymeric carrier is not a capsule.

2. The composition according to claim 1 wherein said composition is formed into microspheres having an average size of between 0.5 and 200 μ

m.

3. The composition according to claim 1 wherein said composition is formed into a film with a thickness of between 100 μ

m and 2 mm.

4. The composition according to claim 1 wherein said composition is liquid above 45°

C., and solid or semi-solid at 37°

C.

5. The composition according to claim 1 wherein said polymeric carrier is poly(ethylene-vinyl acetate) (40% crosslinked).

6. The composition according to claim 1 wherein said polymeric carrier is copolymer of lactic acid and glycolic acid.

7. The composition according to claim 1 wherein said polymeric carrier is poly (caprolactone).

8. The composition according to claim 1 wherein said polymeric carrier is poly (lactic acid).

9. The composition according to claim 1 wherein said polymeric carrier is a copolymer of poly (lactic acid) and poly (caprolactone).

10. The composition according to claim 1 wherein said compound which disrupts microtubule function is paclitaxel.

11. The composition according to claim 1 wherein said compound which disrupts microtubule function is selected from the group consisting of estramustine, colchicine, methotrexate, curacin-A, epothilone, vinblastine and tBCEU.

13. The composition of claim 10 wherein said anti-angiogenic factor is selected from the group consisting of paclitaxel, suramin, methotrexate and lighter d group transition metals.

16. A method for embolizing a blood vessel, comprising delivering into said vessel a therapeutically effective amount of composition according to any one of claims 1-15, such that said blood vessel is effectively occluded.

17. The method according to claim 16 wherein said blood vessel nourishes a tumor.

12. A composition, comprising:

(a) an anti-angiogenic factor; and

(b) hyaluronic acid.

14. A composition comprising:

(a) a lighter d group transition metal which inhibits the formation of new blood vessels; and

a polymeric carrier.

15. The composition according to claim 14 wherein said lighter d group is selected from the group consisting of species of vanadium, molybdenum, tungsten, titanium, niobium and tantalum.

18. A stent, comprising a generally tubular structure, the surface of which is coated with a composition comprising an anti-angiogenic factor and a polymeric carrier.

19. A method for expanding the lumen of a body passageway, comprising inserting a stent into the passageway, the stent having a generally tubular structure, the surface of said structure being coated with a composition comprising an anti-angiogenic factor and a polymeric carrier, such that said passageway is expanded.

20. A method for eliminating vascular obstructions, comprising inserting a vascular stent into a vascular passageway, the stent having a generally tubular structure, the surface of said structure being coated with a composition comprising an anti-angiogenic factor and a polymeric carrier, such that said vascular obstruction is eliminated.

21. A method for eliminating biliary obstructions, comprising inserting a biliary stent into a biliary passageway, the stent having a generally tubular structure, the surface of said structure being coated with a composition comprising an anti-angiogenic factor and a polymeric carrier, such that said biliary obstruction is eliminated.

22. A method for eliminating urethral obstructions, comprising inserting a urethral stent into a urethra, the stent having a generally tubular structure, the surface of said structure being coated with a composition comprising an anti-angiogenic factor and a polymeric carrier, such that said urethral obstruction is eliminated.

23. A method for eliminating esophageal obstructions, comprising inserting an esophageal stent into an esophagus, the stent having a generally tubular structure, the surface of said structure being coated with a composition comprising an anti-angiogenic factor and a polymeric carrier, such that said esophageal obstruction is eliminated.

24. A method for eliminating tracheal/bronchial obstructions, comprising inserting a tracheal/bronchial stent into the trachea or bronchi, the stent having a generally tubular structure, the surface of which is coated with a composition comprising an anti-angiogenic factor and a polymeric carrier, such that said tracheal/bronchial obstruction is eliminated.

25. A method for treating a tumor excision site, comprising administering a composition comprising an anti-angiogenic factor and a polymeric carrier to the resection margin of a tumor subsequent to excision, such that the local recurrence of cancer and the formation of new blood vessels at said site is inhibited.

26. The method according to claim 25 wherein said composition is liquid above 45°

C. and solid or semi-solid at 37°

C.

27. The method according to claim 26 wherein the step of administering comprises spraying microspheres composed of said composition into the resection margin of the tumor.

28. A method for treating corneal neovascularization, comprising administering to a patient a therapeutically effective amount of a composition comprising an anti-angiogenic factor and a polymeric carrier to the cornea, such that the formation of blood vessels is inhibited.

30. The method according to claims 28 or 29 wherein said method further comprises the administration of a topical corticosteroid.

29. A method for treating corneal neovascularization, comprising administering to a patient a therapeutically effective amount of paclitaxel to the cornea, such that the formation of blood vessels is inhibited.

31. A method for inhibiting angiogenesis in patients with non-tumorigenic, angiogenesis-dependent diseases, comprising administering to a patient a therapeutically effective amount of a composition comprising paclitaxel to a patient with a non-tumorigenic angiogenesis-dependent disease, such that the formation of new blood vessels is inhibited.

32. A method for embolizing a blood vessel in a non-tumorigenic, angiogenesis-dependent diseases, comprising delivering to said vessel a therapeutically effective amount of a composition comprising paclitaxel, such that said blood vessel is effectively occluded.

33. A method for expanding the lumen of a body passageway, comprising inserting a stent into the passageway, the stent having a generally tubular structure, the surface of said structure being coated with a composition comprising paclitaxel, such that said passageway is expanded.

34. A method for eliminating vascular obstructions, comprising inserting a vascular stent into a vascular passageway, the stent having a generally tubular structure, the surface of said structure being coated with a composition comprising paclitaxel, such that said vascular obstruction is eliminated.

35. A method for eliminating biliary obstructions, comprising inserting a biliary stent into a biliary passageway, the stent having a generally tubular structure, the surface of said structure being coated with a composition comprising paclitaxel, such that said biliary obstruction is eliminated.

36. A method for eliminating urethral obstructions, comprising inserting a urethral stent into a urethra, the stent having a generally tubular structure, the surface of said structure being coated with a composition comprising paclitaxel, such that said urethral obstruction is eliminated.

37. A method for eliminating esophageal obstructions, comprising inserting an esophageal stent into an esophagus, the stent having a generally tubular structure, the surface of said structure being coated with a composition comprising paclitaxel, such that said esophageal obstruction is eliminated.

38. A method for eliminating tracheal/bronchial obstructions, comprising inserting a tracheal/bronchial stent into the trachea or bronchi, the stent having a generally tubular structure, the surface of said structure being coated with a composition comprising paclitaxel, such that said tracheal/bronchial obstruction is eliminated.

39. A method for treating a tumor excision site, comprising administering to a patient a composition comprising paclitaxel to the resection margin of a tumor subsequent to excision, such that the local recurrence of cancer and the formation of new blood vessels at said site is inhibited.

40. A method for treating neovascular disease of the eye, comprising administering to a patient a therapeutically effective amount of a compound which disrupts microtubule function to the cornea, such that the formation of new vessels is inhibited.

41. The method according to claim 40 wherein said compound which disrupts microtubule function is paclitaxel.

42. The method according to claim 40 wherein said compound which disrupts microtubule function is selected from the group consisting of estramustine, colchicine, methotrexate, curacin-A, epothilone, vinblastine and tBCEU.

43. The method according to claim 40 wherein said neovascular disease is selected from the group consisting of corneal neovascularization and macular degeneration.

44. A method for treating inflammatory arthritis, comprising administering to a patient a therapeutically effective amount of a composition comprising an anti-angiogenic factor and a polymeric carrier to a joint, such that the formation of blood vessels is inhibited, with the proviso that said anti-angiogenic factor is not methotrexate.

45. The method according to claim 44 wherein said anti-angiogenic factor is a compound which disrupts microtubule function.

46. The method according to claim 44 wherein said compound which disrupts microtubule function is selected from the group consisting of estramustine, colchicine, curacin-A, epothilone, vinblastine and tBCEU.

47. The method according to claim 44 wherein said compound which disrupts microtubule function is paclitaxel.

48. A method for inflammatory arthritis, comprising administering to a patient a therapeutically effective amount of an anti-angiogenic factor to a joint, such that the formation of blood vessels is inhibited, with the proviso that said anti-angiogenic factor is not methotrexate.

49. The method according to claim 48 wherein said anti-angiogenic factor is a compound which disrupts microtubule function.

50. The method according to claim 48 wherein said compound which disrupts microtubule function is selected from the group consisting of estramustine, colchicine, curacin-A, epothilone, vinblastine and tBCEU.

51. The method according to claim 48 wherein said compound which disrupts microtubule function is paclitaxel.

52. A composition comprising a polymeric carrier adapted to contain and release a hydrophobic compound, said carrier containing a hydrophobic compound in combination with a carbohydrate, protein or polypeptide.

53. The composition of claim 52 wherein said polymeric carrier is poly(ethylene-vinyl acetate) (40% crosslinked).

54. The composition of claim 52 wherein said polymeric carrier is copolymer of lactic acid and glycolic acid.

55. The composition of claim 52 wherein said polymeric carrier is poly (caprolactone).

56. The composition of claim 52 wherein said polymeric carrier is poly (lactic acid).

57. The composition according to claim 52 wherein said hydrophobic compound is a compound which disrupts microtubule function.

58. The composition according to claim 57 wherein said compound which disrupts microtubule function is paclitaxel.

59. The composition according to claim 57 wherein said compound which disrupts microtubule function is selected from the group consisting of estramustine, colchicine, methotrexate, curacin-A, epothilone, vinblastine and tBCEU.

60. A pharmaceutical product, comprising:

(a) a compound which disrupts microtubule function, in a container; and

(b) a notice associated with said container in form prescribed by a governmental agency regulating the manufacture, use, or sale of pharmaceuticals, which notice is reflective of approval by said agency of said paclitaxel, for human or veterinary administration to treat non-tumorigenic angiogenesis-dependent diseases.

61. The pharmaceutical product according to claim 60 wherein said compound which disrupts microtubule function is paclitaxel.